The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harizi, H.
Right arrow Articles by Gualde, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harizi, H.
Right arrow Articles by Gualde, N.
The Journal of Immunology, 2003, 170: 139-146.
Copyright © 2003 by The American Association of Immunologists

Prostaglandins Inhibit 5-Lipoxygenase-Activating Protein Expression and Leukotriene B4 Production from Dendritic Cells Via an IL-10-Dependent Mechanism1

Hedi Harizi, Monique Juzan, Jean-François Moreau and Norbert Gualde2

Laboratoire d’Immunologie, Center National de la Recherche Scientifique, Unité Mixte de Recherche 5540, Université de Bordeaux 2, Bordeaux, France


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
PGs produced from arachidonic acid by the action of cyclooxygenase enzymes play a pivotal role in the regulation of both inflammatory and immune responses. Because leukotriene B4 (LTB4), a product of 5-lipoxygenase (5-LO) pathway, can exert numerous immunoregulatory and proinflammatory activities, we examined the effects of PGs on LTB4 release from dendritic cells (DC) and from peritoneal macrophages. In concentration-dependent manner, PGE1 and PGE2 inhibited the production of LTB4 from DC, but not from peritoneal macrophage, with an IC50 of 0.04 µM. The same effect was observed with MK-886, a 5-LO-activating protein (FLAP)-specific inhibitor. The decreased release of LTB4 was associated with an enhanced level of IL-10. Furthermore, the inhibition of LTB4 synthesis by PGs was significantly reversed by anti-IL-10, suggesting the involvement of an IL-10-dependent mechanism. Hence, we examined the effects of exogenous IL-10 on the 5-LO pathway. We demonstrate that IL-10 suppresses the production of LTB4 from DC by inhibiting FLAP protein expression without any effect on 5-LO and cytosolic phospholipase A2. Taken together, our results suggest links between DC cyclooxygenase and 5-LO pathways during the inflammatory response, and FLAP is a key target for the PG-induced IL-10-suppressive effects.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Prostaglandins and leukotrienes (LTs)3 are potent eicosanoid lipid mediators derived from phospholipase-released arachidonic acid (AA) that are involved in numerous homeostatic biological functions and inflammation (1). They are produced predominately by cells of myeloid origin (2), by the action of cyclooxygenase (COX) isozymes and 5-lipoxygenase (5-LO), respectively (3). For many years, macrophages have been considered as a major source of eicosanoids. More recently, we have reported that the in vitro generated dendritic cells (DC) produce a full range of eicosanoids, in particular PGE2 and LTB4 (4).

The 5-LO pathway is the major route of AA metabolism leading to the formation of LTs (5). In the first steps of LT biosynthesis, AA liberated by the action of phospholipase A2 (PLA2), in particular cytosolic PLA2 (cPLA2), is transferred to 5-LO by 5-LO-activating protein (FLAP) (6, 7). Upon activation, 5-LO translocates to the nuclear envelope, in which FLAP is localized (8, 9). FLAP binds free AA, presents it to 5-LO, and thus makes easier 5-LO substrate interaction (10). The 5-LO catalyzes the insertion of molecular oxygen into AA to form 5-hydroxyperoxyeicosatetraenoic acid as well as its subsequent dehydration to LTA4 (11, 12). LTA4 is then modified by LTA4 hydrolase to generate LTB4 (13).

LTB4 is a powerful leukotropic, proinflammatory, and immunoregulatory mediator (14, 15). The overproduction of LTB4 plays an important role in the pathogenesis of a variety of inflammatory diseases, including asthma, glomerulonephritis, psoriasis, inflammatory bowel diseases, and acute lung injury (16, 17). Considering their role in host defense against microbial infections (18) and their important pathophysiologic roles in inflammatory states, synthesis of LTs must be highly regulated. Two steps seem to be involved in the control of the formation of these lipid mediators, that is, liberation of AA and regulation of 5-LO activity (19). Moreover, the expression of 5-LO and FLAP, which is subject to regulation in monocytic cells (20), has been considered as the major determinant of cellular LT synthesis (21).

The interactions between eicosanoids may represent means to regulate the release of inflammatory mediators, and may be important for the regulation of cell functions and inflammatory disorders, such as allergic asthma. Previous studies have reported that eicosanoid products of AA metabolism are important modulators of macrophage COX and 5-LO pathways (22). For example, macrophage 5-LO activity may be inhibited by some metabolites of the lipoxygenase pathways (23, 24). PGE2 can modulate the synthesis and metabolism of other lipid mediators (25). It also has been reported that in rat neutrophils, PGE1 or PGE2 (26) could inhibit FMLP-induced synthesis of LTB4. Although many studies involving eicosanoids have been performed on macrophages, little is known about the interactions between these lipid mediators in DC and the mechanism by which PGs may inhibit 5-LO metabolism. Because a report related the inhibition of macrophage LTB4 production by limiting AA availability (27), expression of 5-LO and FLAP by human DC has been noted (28, 29).

High concentrations of exogenous AA have been shown to activate 5-LO enzyme activity as well as providing substrate for LT synthesis (30, 31). However, it has been reported that exogenous AA did not modify macrophage eicosanoid release (32). Early theories have suggested that the blockade of COX pathways by nonsteroidal anti-inflammatory drugs causes shunting of AA into the 5-LO pathway, resulting in the production of high levels of LTB4 and symptoms of asthma. However, the demonstration of the bronchoprotective effect of inhaled PGE2 against aspirin-induced bronchospasm has suggested the inhibitory effect of PGE2 on the 5-LO pathway (33).

Because the interactions between COX and 5-LO pathways may regulate tissue homeostasis and contribute to the modulated production of AA metabolites, we have examined the effects of PGs on the 5-LO pathway, and the mechanism by which PGs modulate 5-LO metabolism. We found that LTB4 does not affect COX expression and PGE2 production from either DC or peritoneal macrophage (PM). By contrast, PGE2 decreases the production of LTB4 from DC. In concentration-dependent manner, PGE2 enhances the production of endogenous IL-10, which inhibits FLAP protein expression and LTB4 production without any effect on cPLA2 and 5-LO protein levels. We obtained the same results with exogenous IL-10, but not with IL-6. Compared with DC, PM exhibited no suppression by PGs of 5-LO metabolism and no induction of endogenous IL-10. Together with the effects of anti-IL-10, our study demonstrates that PGE2 down-regulates DC 5-LO metabolism by inhibiting FLAP protein expression via an IL-10-dependent mechanism.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Media, reagents, and cell cultures

Complete medium (CM) was RPMI 1640 (Life Technologies, Paisley, U.K.) supplemented with 10% heat-inactivated FCS (Dominique Dutscher, Brumath, France), 1% streptomycin (Life Technologies; 1000 µg/ml), 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO), 50 µM 2-ME (Sigma-Aldrich), and 2 mM sodium pyruvate (Life Technologies). DC were generated from mouse bone marrow cells, as we have reported previously (34). Briefly, bone marrow cells isolated from BALB/c mice (Iffa Credo, Lyon, France) were cultured in CM in the presence of GM-CSF (20 ng/ml) and IL-4 (10 ng/ml) (PeproTech, Rocky Hill, NJ) for 6 days. Bone marrow DC were positively purified (routinely >98% CD11c+) using anti-CD11c (N418) MicroBeads and magnetic cell separation system column (Miltenyi Biotec, Bergisch Gladbach, Germany). Mouse PM were obtained by peritoneal lavage with 5 ml of RPMI 1640, massage of the peritoneum, and drawing back of the fluid into the syringe. Inhibitors used in our study were dissolved in absolute ethanol (Merck, Darmstadt, Germany) and stored as stock solutions of 1 mM at -20°C. The required dilutions were prepared immediately before use, and equivalent quantities of ethanol were added to the cultures to serve as controls for these drugs.

Assessment of eicosanoid production

Day 6 DC and freshly isolated PM (1 x 106/ml) were incubated for 18 h in CM alone or with 5 µM of calcium ionophore A-23187 (Sigma-Aldrich). Some A-23187-treated cells were stimulated with 1 µg/ml of LPS in the absence and the presence of COX inhibitors (4 µM of indomethacin and 10 µM of NS-398; Cayman Chemicals, Ann Arbor, MI). To examine the effect of exogenous prostanoids on LTB4 production, A-23187-stimulated cells (1 x 106/ml) were incubated in CM with increasing concentrations of exogenous PGE1, PGE2, or thromboxane B2 (TXB2) (Calbiochem, Meudon, France) for 18 h at 37°C. Parallel cultures of A-23187-stimulated DC and PM were incubated for 18 h in the presence of 1 µM of exogenous PGE2. The effects of PGE2 on LT production from exogenous substrate were analyzed in DC stimulated with calcium ionophore in the presence of 1 µM of exogenous PGE2. Exogenous AA was added to cell culture for 30 min after 18 h of incubation. We also examined the concentration-dependent effect of MK-886, a FLAP-specific inhibitor (Biomol Research Laboratories, Plymouth Meeting, PA), and nor-dihydroguaiaretic acid (NDGA), a 5-LO inhibitor (Sigma-Aldrich), on the production of PGE2 and LTB4 from endogenous AA. The various prostanoids and drugs used did not affect the number of viable cells quantified by MTT essay. Cell-free supernatants were harvested, and commercial ELISA kits (Cayman) measured eicosanoid production. The detection limits for PGE2 and LTB4 are 15 and 4 pg/ml, respectively.

Preparation of cytoplasmic and nuclear extracts and Western blot analyses

Cytoplasmic lysates were prepared, as described previously (35). Briefly, following the designated treatments, PM and the in vitro generated DC obtained at 98% purity were washed twice with PBS and lysed in ice-cold lysis buffer containing 10 mM HEPES (pH 7.6), 3 mM MgCl2, 40 mM KCl, 2 mM DTT, 0.5% Nonidet P-40, 8 µg/ml leupeptin, and 10 µg/ml PMSF. Nuclei were removed by centrifugation (1250 x g at 4°C for 5 min). Nuclei were then resuspended and sedimented twice in the lysis/extraction buffer to avoid contamination by cytoplasmic proteins. Nuclear extracts were prepared from the pelleted nuclei in the nuclear extraction buffer containing 10 mM HEPES (pH 7.9), 0.1 mM EGTA, 1.5 mM MgCl2, 420 mM NaCl, 0.5 mM DTT, 0.5 mM PMSF, and 25% glycerol. After incubation in ice for 20 min, cellular debris were removed by centrifugation (1250 x g at 4°C for 5 min). The bicinchoninic acid protein assay reagent (Pierce, Rockford, IL) was used to analyze protein concentration. Nuclear and cytoplasmic extracts (15 µg protein/lane) were resolved on SDS-polyacrylamide gels, and Western blotting analyses were performed using an ECL kit (Amersham, Little Chalfont, U.K.). The blots were probed with specific Abs directed against cPLA2 (1/1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA), 5-LO (1/500 dilution; BD Transduction Laboratories, Lexington, KY), and {alpha}-tubulin (2/10,000; Sigma-Aldrich). The rabbit polyclonal antisera to FLAP, which have been extensively characterized (8), was generously provided by J. F. Evans (Merck Frosst Center for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada). Used at 1/300 dilution, the antisera to FLAP (designated H4 TB4) were raised against the thyroglobulin conjugate of aa residues 41–52 of FLAP. This region is completely conserved between human and murine FLAP. Protein bands were detected with the ECL Western blotting analysis system from Amersham.

Assessment of IL-10 production and effects of anti-IL-10 and exogenous cytokines on LTB4 release

IL-10 level was measured using the commercially available ELISA kit, according to the manufacturer’s instructions (Quantikine mouse IL-10 immunoassay; R&D Systems, Abingdon, U.K.), in the supernatants of cells treated for 18 h with increasing concentrations of TXB2 or PGE2. The detection limit of the endogenously produced IL-10 is 4 pg/ml. To investigate whether PGE2-induced IL-10 mediated suppression of LTB4 production, PGE2-treated cells were incubated for 18 h with 100 ng/ml of anti-IL-10-neutralizing Ab (purified rat anti-mouse IL-10 mAb, clone JES5-16E3; BD PharMingen, San Diego, CA) or isotype control (purified rat IgG2b; BD PharMingen). We also examined the effect of exogenous cytokines on LTB4 production from A-23187-stimulated cells treated for 18 h with graded concentrations of IL-10 or IL-6 (mouse rIL-10, rIL-6; PeproTech). IL-6 was selected in our study for its role in inducing the acute phase response and down-regulating inflammatory processes (36). No one exogenous cytokine used affected the number of viable cells quantified by MTT essay. All supernatants were collected for LTB4 measurement.

Effect of exogenous LTB4 on COX pathways

To investigate the interaction between COX and 5-LO pathways, DC and LPS-stimulated DC were treated with increasing concentrations of exogenous LTB4 (Sigma-Aldrich) for 18 h. The various concentrations used did not affect the number of viable cells quantified by MTT essay. At the end of culture period, cells were collected for the analysis of COX protein expressions by Western blotting, as we have recently reported (4), and supernatants were used for the measurement of PGE2 production by ELISA.

Cell viability

The viability of DC and PM was measured using the MTT essay, which is routinely used in our laboratory. In brief, cells (4 x 106/ml) were incubated in flat-bottom 96-well plates in the presence of 5 mg/ml MTT (Sigma-Aldrich) for 4 h at 37°C. The precipitates were dissolved by adding 0.115 ml of isopropyl alcohol containing 1% formic acid, and the absorbance was measured at 570 nm (Titertek Labsystems Multiskan reader, Turku, Finland).

Statistical analysis

The results are expressed as the mean ± SEM. Analysis of data was performed using Student’s t test; p < 0.01 was considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
A-23187 enhances the translocation of 5-LO and cPLA2 to the nuclear envelope and increases the release of LTB4

Compared with control cells, the incubation of DC with calcium ionophore A-23187 for 18 h had no significant effect on the percentage of viable cells (96%) quantified by MTT essay. Because we knew little about the intracellular location of the LT enzymatic machinery in DC, we examined the intracellular trafficking and location of the enzymes involved in the biosynthesis of LTs from endogenous AA. DC were gently disrupted (the plasma membrane, but not the nuclear membrane, was ruptured) and separated into nuclear and cytosolic fractions that were then subjected to immunoblot analysis. Western blot analyses (Fig. 1GoA) show that FLAP was found predominately in the nuclear fraction of both resting and activated cells. In agreement with other investigators (37), 5-LO and cPLA2 were found to redistribute from the cytosolic to the nuclear fraction of activated cells. The same results were observed in PM (data not shown). cPLA2 hydrolyzes nuclear membrane phospholipids to release AA, which binds to FLAP for presentation to 5-LO for oxygenation. The ionophore activation of DC and PM results in the enhancement of LTB4 release, but had no significant effect on the production of PGE2 (Fig. 1GoB). Our results suggest that the nuclear envelope is a potent intracellular site at which 5-LO and FLAP interact for efficient LT release, and the association of cPLA2, 5-LO, and FLAP plays a key role in the modulated biosynthesis of LTs.



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 1. Calcium ionophore A-23187 stimulates the translocation of 5-LO and cPLA2 to the nuclear envelope and enhances the production of LTB4 from endogenous AA. Cells (1 x 106/ml) were cultured for 18 h in CM with (Activated) and without (Resting) 5 µM of calcium ionophore A-23187. Subsequently, A, cellular expression of 5-LO, FLAP, and cPLA2 was analyzed by Western blot in the nuclear (N) and cytoplasmic (C) extracts from resting and activated cells. B, PGE2 and LTB4 production was measured in cell-free supernatants by ELISA. One of six representative Western blots is shown. Each value of eicosanoid level represents the mean (±SEM) of six independent experiments.

 
Effect of COX inhibitors on the production of eicosanoids from DC and PM

The in vitro generated DC have all the enzymatic tools to synthesize PGE2 and LTB4, the major COX and 5-LO metabolites, respectively. The production of PGE2 and LTB4 did not require the addition of exogenous substrate, because DC possess an active cPLA2, which catalyzes the liberation of endogenous AA from membrane phospholipids. As shown in Fig. 2GoB (Control), DC produce low levels of PGE2 and LTB4, when compared with PM (Fig. 2GoA, Control), from which production of LTB4 is 2-fold higher. In addition, results obtained in Fig. 2GoA show that PM COX and 5-LO pathways prevail in terms of eicosanoid production from endogenous AA. However, in DC, COX metabolism of endogenous AA is greater than 5-LO pathway, in particular when cells were stimulated with LPS (Fig. 2GoB). In fact, we have recently demonstrated that following LPS stimulation, DC strongly express COX-2 protein, the predominant isoform of COX, which induces a production of high levels of PGE2 (4). The production of PGE2 from LPS-stimulated DC is 3-fold higher when compared with control cells (Fig. 2GoB). The blockade of COX pathway by COX inhibitors significantly increased the production of LTB4 from DC (+100%), but not from PM (Fig. 2Go). These results suggest that COX metabolites, in particular PGE2, may inhibit the production of LTB4 from DC. These observations argue in favor of links between COX and 5-LO pathways in DC. However, these two oxidative pathways of AA metabolism seem to be independent in PM.



View larger version (17K):
[in this window]
[in a new window]
  		FIGURE 2. COX inhibitors enhance the production of LTB4 from DC, but not from PM. A-23187-stimulated cells (1 x 106/ml) were incubated for 18 h with 1 µg/ml LPS in the absence and the presence of COX inhibitors. Control included activated cells cultured in CM alone. The production of PGE2 and LTB4 was measured by ELISA in cell-free supernatants from PM (A) and DC (B). Each value represents the mean (±SEM) of six independent experiments.

 
Role of FLAP in 5-LO metabolism

Several lines of evidence have advanced a model for the initiation of LT biosynthesis in which FLAP plays a critical role in LT production. This evidence includes studies of LT biosynthesis in cells transfected with transgenes encoding 5-LO and FLAP (38), as well as studies of LT inhibitors, such as MK-886. MK-886 is known to bind to FLAP and prevent the synthesis of LTs from endogenous AA in intact cells, by blocking membrane association of 5-LO (39). However, other reports state that MK-886 may inhibit LT biosynthesis without any effect on membrane association (9, 40), suggesting that LT biosynthesis can be a tow-step process consisting of FLAP-independent binding of 5-LO to the membrane of the nuclear envelope, followed by FLAP-dependent activation of the enzyme. In our study, treatment of A-23187-stimulated DC with graded concentrations of MK-886, a FLAP-specific inhibitor (Fig. 3GoA), or NDGA, a 5-LO inhibitor (Fig. 3GoB), concentration dependently decreases the production of LTB4 with an IC50 of 2.8 nM and 5 µM, respectively. There is no significant difference between DC and PM in terms of drug-inhibitory effect on 5-LO metabolism (data not shown). A concentration of 4 nM of MK-886, which did not affect cell viability, totally suppresses LTB4 release from endogenous AA. However, we observed no effect of MK-886 on the production of PGE2, suggesting that the blockade of FLAP did not affect COX metabolism. The same results were observed with NDGA.



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 3. MK-886 and NDGA concentration dependently inhibit the production of LTB4 from DC without any effect on PGE2 release. A-23187-stimulated DC were incubated for 18 h in CM with graded concentrations of MK-886 (A) or NDGA (B). At the end of incubation period, cell-free supernatants were harvested, and the production of PGE2 and LTB4 was measured by ELISA. Each value represents the mean (±SEM) of six independent experiments.

 
PGs inhibit the release of LTB4 from DC

Incubation of DC for 18 h in the presence of graded concentrations of PGE1 or PGE2, which had no effect on the cell viability, led to concentration-dependent decreases in the A-23187-stimulated production of LTB4 with an IC50 of 0.04 µM (Fig. 4GoA). These results show that PGE1 and PGE2 are both potent inhibitors of the production of LTB4 by activated DC. However, TXB2, a product of COX pathway, failed to inhibit the release of LTB4 from DC. The IC50 value for both PGE1 and PGE2 for the inhibition of LTB4 production is in the physiological range. The effect of PGE2 on the production of LTB4 from PM was examined in similar conditions. As shown in Fig. 4GoB, although a concentration of 1 µM of exogenous PGE2 decreases the production of LTB4 from DC (p < 0.01), it failed to significantly inhibit the release of LTB4 from endogenous AA in PM. A modest decrease in LTB4 release was observed in PM when compared with DC in the same conditions. LT biosynthesis from endogenous AA requires both PLA2-mediated deacylation of AA and FLAP-dependent binding and presentation of AA to 5-LO. We next examined the effect of PGE2 treatment on 5-LO metabolism from exogenous AA, which bypasses the necessity for AA release by cPLA2, and reduces the reliance on FLAP by presenting large amounts of the substrate AA directly to the 5-LO enzyme. Interestingly, we found that the exogenously added AA failed to significantly enhance the production of LTB4 from DC, and did not significantly reverse the inhibitory effect of PGE2 on 5-LO metabolism (Fig. 4GoC). Although the inhibitory effect of PGE2 on the biosynthesis of LTs from endogenous AA is clearly established, the modulation of 5-LO metabolism from exogenous substrate appears to be complex. Our results, however, suggest that PGs did not inhibit 5-LO metabolism by limiting substrate availability. Together with the results obtained with COX inhibitors, we demonstrate that the shunting of AA into 5-LO pathway did not explain the increased level of LTB4 following the treatment of cells with COX inhibitors, and PGs down-regulate LTB4 release via an AA-independent mechanism.



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 4. PGE1 and PGE2 inhibit the A-23187-induced release of LTB4 from DC, but not from PM with an AA-independent mechanism. A, A-23187-stimulated DC were incubated in the presence of graded concentrations of prostanoids, as described in Materials and Methods. After 18 h of incubation, the production of LTB4 was measured by ELISA, and data are represented as percentage of LTB4 levels measured in the absence of exogenous prostanoids. B, PM and DC were treated with 1 µM of PGE2, and the level of LTB4 was measured in the supernatant after 18 h of incubation. C, The production of LTB4 from exogenous AA was measured in the supernatant of A-23187-stimulated DC treated with PGE2 in the presence of 10 µM of exogenous AA. Each value represents the mean (±SEM) of eight independent experiments.

 
PGE2 enhances the production of endogenous IL-10 from DC, but not from PM

Supernatants from various culture conditions (see Materials and Methods) were analyzed by ELISA to determine the production of IL-10 and IL-6 in response to prostanoid treatment. As shown in Fig. 5GoA, TXB2 has no effect on IL-10 release from DC and from PM. We also observed no effect on IL-6 release (data not shown). However, when DC were cultured for 18 h in the presence of graded concentrations of PGE2, significant stimulation of endogenous IL-10 was observed in DC, but not in PM (Fig. 5GoB). The same results were obtained with PGE1 (data not shown). A concentration of 1 µM of PGE2, which causes a 94% decrease in LTB4 release (see Fig. 4GoB), resulted in the production of 2 ng/ml of endogenous IL-10. In contrast, PGE2 lacked any significant effect on the production of IL-6 (data not shown).



View larger version (14K):
[in this window]
[in a new window]
  		FIGURE 5. PGE2 concentration dependently enhances the production of endogenous IL-10 from DC, but not from PM. Activated cells (1 x 106/ml) were incubated in CM with graded concentrations of PGE2 or TXB2. After 18 h of incubation, supernatants were harvested, and the production of cytokines from PM (A) and DC (B) was measured by ELISA. Each value represents the mean (±SEM) of six independent experiments.

 
Inhibition of LTB4 release by PGE2 was totally reversed by anti-IL-10

To determine whether the increase in IL-10 production by PGE2 was responsible for its inhibitory effect on 5-LO metabolism of endogenous AA, PGE2-treated DC were incubated in the presence of 100 ng/ml of anti-IL-10 or isotype control Abs for 18 h. As we reported before (4), the concentration of 100 ng/ml anti-IL-10 induced the neutralization of >95% of the endogenously induced IL-10. Results obtained in Fig. 6Go showed that the inhibitory effect of PGE2 on LTB4 release was totally reversed by anti-IL-10, but not by isotype control, suggesting the involvement of an IL-10-dependent mechanism in the inhibition of DC LTB4 release by PGs.



View larger version (13K):
[in this window]
[in a new window]
  		FIGURE 6. Anti-IL-10 Ab totally reverses the PGE2-inhibitory effect on LTB4 release from DC. PGE2-treated DC were incubated for 18 h in the presence of 100 ng/ml anti-IL-10 or isotype control, as was described in Materials and Methods. Subsequently, the production of LTB4 was measured by ELISA in cell-free supernatants. Results of six independent experiments were expressed as percentage of LTB4 release in the presence of exogenous PGE2.

 
Effects of exogenous IL-10 and PGE2 on the expression of cPLA2, FLAP, and 5-LO proteins

We next determined whether PGE2-mediated inhibition of LTB4 release is associated with changes in 5-LO, FLAP, or cPLA2 protein expressions. Western blot analyses showed that PGE2 had no effect on the expression of 5-LO either in DC or in PM (Fig. 7GoA). It also did not affect the cPLA2 protein expression and AA release from DC (data not shown). In contrast, incubation of cells with increasing concentrations of PGE2 inhibits, in concentration-dependent manner, the expression of FLAP protein in DC, but not in PM. A reproducible and representative Western blot is shown in Fig. 7GoB. The same results were obtained when cells were incubated for 18 h with graded concentrations of exogenous IL-10 (Fig. 8GoA), which caused a concentration-dependent inhibition of LTB4 release from DC (Fig. 8GoB). A concentration of 1 ng/ml IL-10 significantly down-regulates FLAP protein expression and decreases (minus 80%) LTB4 production from A-23187-stimulated DC. However, no effect on the expression of either FLAP or 5-LO proteins was observed in response to exogenous IL-6 (data not shown). Taken together, our results demonstrate that FLAP is a target for the PG-induced IL-10-suppressive effects.



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 7. Exogenous PGE2 concentration dependently inhibits the expression of FLAP in DC, but not in PM, without any effect of 5-LO. PM and DC were treated with graded concentrations of PGE2, as described in Materials and Methods. After 18 h of incubation, the expression of FLAP and 5-LO protein was analyzed by Western blot in the nuclear extracts. A, No change in the 5-LO-immunoblotting signal was observed either in PM or in DC. B, PGE2 decreases in concentration-dependent fashion the expression of FLAP in DC, but not in PM. One of six representative Western blots is shown.

 


View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 8. Exogenous IL-10 down-regulates DC 5-LO metabolism by inhibiting, in concentration-dependent manner, the expression of FLAP without any effect on cPLA2 and 5-LO protein levels. A-23187-stimulated DC were incubated for 18 h in CM with graded concentrations of exogenous IL-10. A, Nuclear extracts prepared as described in Materials and Methods were analyzed by Western blot for the expression of cPLA2, FLAP, and 5-LO protein. B, The production of LTB4 was measured in the cell-free supernatants. One of six representative Western blots is shown. Each value represents the mean (±SEM) of six independent experiments.

 
LTB4 does not affect COX pathways

The findings that PGE2 release is associated with inflammatory states suggest that other lipid mediators, such as LTB4, might modulate its production. Moreover, the 5-LO metabolite of AA, LTB4, has been shown to exert numerous proinflammatory activities, such as the induction of IL-6 gene expression and cytokine release from human monocytes (41). Recently, we have shown that LTB4 had no effect on the production of IL-10 and IL-12 from DC (4). When we examined the effect of LTB4 on the COX pathways, we found that this 5-LO metabolite did not affect COX expression (Fig. 9GoA) and PGE2 production (Fig. 9GoB) from in vitro generated DC. These results confirm the effects of MK-886 and NDGA used to block the endogenous biosynthesis of LTB4 (Fig. 3Go), and demonstrate that the endogenously produced or the exogenously added LTB4 had no effect on COX metabolism.



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 9. LTB4 does not affect COX expression and PGE2 production from DC. DC and DC stimulated with 1 µg/ml LPS were incubated in the presence of increasing concentrations of exogenous LTB4, which had no effect on the cell viability. A, The expression of both isoforms of COX was analyzed in the cytoplasmic extracts, as we have recently reported (4 ), and B, the production of PGE2 was assessed by ELISA in the cell-free supernatants. One of six representative Western blots is shown. Each value represents the mean (±SEM) of six independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Considering the many actions of the PGs and LTs, some in mimicry and some in opposition to each other, it is reasonable to expect important interactions to occur between these two groups of compounds. This is truer in view of the fact that products of both pathways derive from the same precursor, AA, and possibly even from the same substrate pool. The inflammatory response induced by AA could be virtually eliminated by the COX inhibitor, indomethacin, in 5-LO-deficient mice, but not in normal animals, suggesting links between COX systems and 5-LO pathway during inflammatory reaction (42).

There are a number of reports that nonsteroidal anti-inflammatory drugs, acting by inhibiting PG synthesis, enhance LT biosynthesis (43, 44), and the existence of a group of people who respond to aspirin and other such drugs with symptoms of asthma emphasizes the importance of these phenomena (45). Because AA is substrate common to both pathways, this enhancement of LT synthesis has been attributed to the shunting of substrate from the PG to the LT pathway (43, 44). In considering the question of the shunting of AA from one pathway to the other, it is necessary to consider whether added AA alone can result in the synthesis of LTs. The cytosolic nature of 5-LO does not foster the concept that exogenously added AA would necessary stimulate LT synthesis. Such an action would require circumvention of triglycerides and phospholipid-forming enzymes present throughout the cell for the accumulation of free AA within the cytosol in quantities sufficient to result in the formation of LTs. In agreement with other investigators (32), we show that the addition of exogenous substrate to the DC cultures had no significant effect on the generation of any of the eicosanoids measured. These results suggest that the enhanced level of LT synthesis is not due to the shunting of AA from COX to 5-LO pathway. The inability of exogenous PGs to affect cPLA2 expression and AA release from DC would argue in favor of an AA-independent mechanism, and PGs did not suppress 5-LO metabolism by limiting substrate availability.

The enzyme 5-LO catalyzes the initial steps in the synthesis of LT from AA. For this reason, LT synthesis is critically dependent on processes that modulate 5-LO activity. The 5-LO activity and product generation might be modulated in multiple ways (46). For example, it has recently become apparent that the intracellular compartmentalization of the 5-LO metabolism affects the integrated output of this biosynthetic pathway (47). Another possibility is modulating the expression and activity of the enzymatic components through transcriptional or posttranscriptional mechanisms. It has also been demonstrated that the nuclear import of 5-LO can modulate LT biosynthesis, because nuclear import of 5-LO can strongly enhance (48) or suppress (49) 5-LO activity. Recently, Flammand et al. (50) have reported that PGE2 and other cAMP-elevating agents down-regulated LT biosynthesis by inhibiting 5-LO translocation to the nuclear envelope in human polymorphonuclear leukocytes (PMN). In our study, we observed that 5-LO protein was found in the nuclear envelope when activated DC were treated with exogenous PGE2 (data not shown), suggesting that this lipid mediator did not suppress LT biosynthesis by inhibiting 5-LO translocation to the nuclear envelope of DC. Our results may only apply to our experimental conditions, and they may differ with alternate matrices, cell types, or culture conditions. In considering the question of 5-LO translocation and its localization, it is necessary to consider that 5-LO can move in or out of the nucleus in response to in vivo or in vitro experimental conditions (47).

Ham et al. (26) were the first to demonstrate that PGE2 inhibited LT biosynthesis. Although much effort has been focused on understanding the mechanism by which PG inhibit 5-LO metabolism in cells, such as PMN, little is known about the regulation of LT metabolism in DC. The results presented in this work represent the first description of a new mechanism by which PGs suppress LT biosynthesis in DC. Compared with LTB4, which had no effect on COX pathways and cytokine release (4), PGE2 concentration dependently enhances the production of endogenous IL-10, which inhibits FLAP expression and LTB4 production from DC. These results demonstrate that IL-10 plays an essential role in modulating LT biosynthesis by inhibiting the expression of FLAP in DC. Although we and others have reported that some inhibitory effects of PGs on DC functions are mediated by the endogenously induced IL-10 (4, 51), to our knowledge, there have been no reports that the expression of FLAP is down-regulated by IL-10. Recently, other investigators have reported that Th2-derived cytokines, such as IL-4 and IL-13, enhanced the A-23187-stimulated production of LTB4 and increased the expression of LTA4 hydrolase, but not those of cPLA2 and 5-LO in human PMN leukocytes (52). They also have demonstrated that IL-10 had no effect on the 5-LO metabolism. One can explain the discrepancy between the two reports because authors adopted a quite different model from the one we used. The present study demonstrates that the down-regulation of 5-LO metabolism by the PG-induced IL-10 is specifically attributable to FLAP, but not to cPLA2 or 5-LO. However, it does not exclude a possible action of PGs on LTA4 hydrolase, which catalyzes the final step in LTB4 synthesis. Because FLAP is the target of the PG-inhibitory effect, other 5-LO products, in particular LTC4 and LTD4, which are increasingly incriminated in the pathogenesis of several inflammatory diseases, such as asthma, would expect to decrease after PG treatment.

Our study shows that FLAP plays pivotal role in the interaction between COX and 5-LO pathways. However, a number of questions remain concerning the mechanism by which FLAP stimulates 5-LO activity. The translocation of 5-LO from cytosol to nuclear envelope in which FLAP is located, and the inability of the exogenously added AA to increase 5-LO metabolism suggest that FLAP is not only required for binding and presenting AA to 5-LO, but also involved in modulating 5-LO activity. Accordingly, a stable complex would be required to form at the membrane between 5-LO, FLAP, cPLA2, and possibly other proteins, and could regulate the interaction of 5-LO with its substrate for an efficient LT production.

The general consensus is that PGs, in particular PGE2, act to shift the immune response toward a type 2 cytokine profile. For example, DC are not refractory to the effects of PGE2 because the exogenously added or the endogenously released PGE2 acts on the DC themselves by inhibiting IL-12 production (4) and MHC class II expression (34), limiting their ability to act as potent APC. Moreover, this lipid mediator can also up-regulate IgE production (53), and may consequently support the development of type 2 cytokine-associated inflammatory disorders. However, there is evidence for a bronchoprotective role for PGE2 in asthma (33, 54, 55). The effects of this lipid mediator on Th1/Th2 responses are sometimes opposite. For example, it has been shown recently that in BALB/c mouse, COX inhibition enhances the production of IL-13 (56). Additional cofactors or cellular interactions may be lacking in the in vitro models.

Our study shows some differences between DC and PM in terms of FLAP expression and eicosanoid production. The blockade of COX pathways enhanced the 5-LO metabolism of endogenous AA and resulted in a significant increase in LTB4 production from DC, but not from PM, suggesting no links between PM COX and 5-LO pathways. It is quite possible that COX and 5-LO metabolites derive from the same pool of AA in DC and from two distinct pools of substrates in PM, as was reported by others (57). We also observed that DC and PM differ in terms of cellular response to exogenous PGE2. This may be due to a different pattern of E prostanoid receptor expression and signaling pathways.

Cells that produce lipid mediators, such as PGE2, or become targets of their actions can also produce other inflammatory mediators, such as AA metabolites and cytokines. The limited capacity of DC to synthesize LTs in the presence of PGs issued from the induced COX-2 enzyme or produced by other cells may underestimate their potential contribution to the generation of these lipid mediators at the site of inflammation. The inhibition of LT release by PGs via endogenous IL-10 could be of particular significance as a potential anti-inflammatory and possibly also an antibroncho-obstructive effect. However, although this reduction of 5-LO metabolism in the setting of PG or IL-10 exposure may represent an endogenous mean to limit the inflammatory response, it may at the same time increase susceptibility to infections, and COX inhibitors may have utility in restoring LT release.


   Acknowledgments
 
We thank Dr. James S. Goodwin (University of Texas Medical Branch, Galveston, TX) for critically reading the manuscript and for his constructive comments. We are grateful to Drs. Jilly F. Evans and A. Ford-Hutchinson (Merck Frosst Center for Therapeutic Research) for generous gifts of antisera to FLAP.


   Footnotes
 
1 This work was supported by La Ligue Régionale Contre Le Cancer, Comité Départemental des Charentes, and Comité Départemental de Gironde. Back

2 Address correspondence and reprint requests to Dr. Norbert Gualde, Laboratoire d’Immunologie, Center National de la Recherche Scientifique, Unité Mixte de Recherche 5540, Université de Bordeaux 2, 33076 Bordeaux Cedex France. E-mail address: norbert.gualde{at}umr5540.u-bordeaux2.fr Back

3 Abbreviations used in this paper: LT, leukotriene; AA, arachidonic acid; CM, complete medium; COX, cyclooxygenase; PLA2, phospholipase A2; cPLA2, cytosolic PLA2; DC, dendritic cell; 5-LO, 5-lipoxygenase; FLAP, 5-LO-activating protein; NDGA, nor-dihydroguaiaretic acid; PM, peritoneal macrophage; PMN, polymorphonuclear leukocyte; TXB2, thromboxane B2. Back

Received for publication July 17, 2002. Accepted for publication October 17, 2002.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Funk, C. D.. 2001. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294:1871.[Abstract/Free Full Text]
  2. Byrum, B. S., J. L. Goulet, R. J. Griffits, B. H. Koller. 1997. Role of 5-lipoxygenase-activating protein in murine acute inflammatory responses. J. Exp. Med. 17:1065.
  3. Rosenbach, T., J. Czernielewski, M. Hecker, B. Czarnetzki. 1990. Comparison of eicosanoid generation by highly purified human Langerhans cells and keratinocytes. J. Invest. Dermatol. 95:104.[Medline]
  4. Harizi, H., M. Juzan, V. Pitard, J.-F. Moreau, N. Gualde. 2002. Cyclooxygenase-2-issued PGE2 enhances the production of endogenous IL-10, which down-regulates the dendritic cell functions. J. Immunol. 168:2255.[Abstract/Free Full Text]
  5. Samulesson, B., S. E. Dahlen, J. A. Lindren, C. A. Rouzer, N. C. Serhan. 1987. Leukotrienes and lipoxins: structure, biosynthesis, and biological functions. Science 237:1171.[Abstract/Free Full Text]
  6. Mancini, J. A., M. Abramovitz, M. E. Cox, E. Wong, S. Charleson, H. Perrier, Z. Wang, P. Prasit, P. J. Vickers. 1993. 5-Lipoxygenase-activating protein is an arachidonate binding protein. FEBS Lett. 318:277.[Medline]
  7. Abramovitz, M., M. E. Cox, E. Wong, C. D. Richardson, C. Li, P. J. Vickers. 1993. 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur. J. Biochem. 215:105.[Medline]
  8. Woods, J. W., J. F. Evans, D. Ethier, S. Scott, P. J. Vickers, L. Hearn, J. A. Heilbein, S. Charleson, I. I. Singler. 1993. 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J. Exp. Med. 178:1935.[Abstract/Free Full Text]
  9. Woods, J. W., M. J. Coffey, T. G. Brock, I. I. Singler, M. Peters-Golden. 1995. 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. J. Clin. Invest. 95:2035.
  10. Vickers, P. J.. 1995. 5-Lipoxygenase-activating protein (FLAP). J. Lipid Mediators Cell Signaling 12:184.
  11. Samuelsson, B., C. D. Funk. 1989. Enzymes involved in the biosynthesis of leukotriene B4. J. Biol. Chem. 264:19469.[Free Full Text]
  12. Needelman, P., J. Turk, B. A. Takschik, A. R. Morrison, J. B. Lefkowith. 1986. Arachidonic acid metabolism. Annu. Rev. Biochem. 55:69.[Medline]
  13. Haeggstrom, J. Z., A. Wetterholm, J. F. Medina, B. Samuelsson. 1993. Leukotriene A4 hydrolase: structure and functional properties in the active center. J. Lipid Mediators 6:1.
  14. Ford-Hutchinson, A. W., M. A. Bray, M. V. Doig, M. E. Shipley, M. J. H. Smith. 1980. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286:264.[Medline]
  15. Rola-Pleszczynski, M.. 1985. Immunoregulation by leukotrienes and other lipoxygenase metabolites. Immunol. Today 10:302.
  16. Lewis, S. A., K. F. Austen, R. J. Soberman. 1990. Leukotrienes and other products of the 5-LO pathway, biochemistry and relation to the pathobiology in human diseases. N. Engl. J. Med. 323:645.[Medline]
  17. Goetzl, E. J., W. L. Smith. 1995. Specificity of expression and effect of eicosanoid mediators in normal physiology and human diseases. FASEB J. 9:1051.[Abstract]
  18. Bailie, M. B., T. J. Standiford, L. L. Laichalk, M. J. Coffey, R. M. Strieter, M. Peters-Golden. 1996. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumoniae in association with decreased alveolar macrophage phagocytic and bactericidal activities. J. Immunol. 157:5221.[Abstract]
  19. Steinhilber, D.. 1994. 5-Lipoxygenase: enzyme expression and regulation of activity. Pharm. Acta Helv. 69:3.[Medline]
  20. Bennett, C. F., M.-Y. Chiang, B. P. Monia, S. T. Crooke. 1993. Regulation of 5-lipoxygenase and 5-lipoxygenase-activating protein expression in HL-60 cells. Biochem. J. 289:33.
  21. Nassar, G. M., A. Montero, M. Fukunaga, K. F. Badr. 1997. Contrasting effects of proinflammatory and T-helper lymphocyte subset-2 cytokines on the 5-lipoxygenase pathway in monocytes. Kidney Int. 51:1520.[Medline]
  22. Elliot, G. R., A. P. M. Lauwen, I. L. Bonta. 1989. Prostaglandin E2 inhibits and indomethacin and aspirin enhance A-23487-stimulated leukotriene B4 synthesis by rat peritoneal macrophages. Br. J. Pharmacol. 96:265.[Medline]
  23. Chang, J., B. Lamb, L. Marinari, A. Kreft, A. J. Lewis. 1985. Modulation by hydroxyeicosatetraenoic acid of arachidonic acid metabolism in mouse resident peritoneal macrophages. Eur. J. Pharmacol. 107:215.[Medline]
  24. Humes, J. L., E. E. Opas, M. Galavage, D. Soderman, R. J. Bonney. 1986. Regulation of macrophage eicosanoid production by hydroperoxy and hydroeicosatetraenoic acid. Biochem. J. 233:199.[Medline]
  25. Elliott, G. R., M. J. Van Batenburg, L. L. Bonta. 1985. Differential regulation of the cyclooxygenase pathway in starch elicited rat peritoneal macrophages by prostaglandin E2. Eur. J. Pharmacol. 114:71.[Medline]
  26. Ham, E. A., D. D. Soderman, M. E. Zanetti, H. W. Dougherty, E. McCauley, F. A. Kuehl, Jr. 1983. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc. Natl. Acad. Sci. USA 80:4349.[Abstract/Free Full Text]
  27. Christman, B. W., J. W. Christman, R. Drowski, I. A. Blair, C. Prakash. 1993. Prostaglandin E2 limits arachidonic availability and inhibits leukotriene B4 synthesis in rat alveolar macrophages. J. Immunol. 151:2096.[Abstract]
  28. Spanbroek, R., M. Hildner, D. Steinhilber, N. Fusenig, K. Yoneda, O. Radmark, B. Samuelsson, A. J. Habenicht. 2000. 5-Lipoxygenase expression in dendritic cells generated from CD34+ hematopoietic progenitors and in lymphoid organs. Blood 96:3857.[Abstract/Free Full Text]
  29. Spanbroek, R., H. J. Stark, U. Janssen-Timmen, S. Kraft., M. Hildner, T. Andl, F. X. Bosch, N. Fusenig, T. Bieber, O. Radmark, et al 1998. 5-Lipoxygenase expression in Langerhans cells of normal human epidermis. Proc. Natl. Acad. Sci. USA 95:663.[Abstract/Free Full Text]
  30. Coffey, M. J., S. E. Wilcoxen, M. Peters-Golden. 1994. Increases in 5-lipoxygenase-activating protein expression account for enhanced capacity of 5-lipoxygenase metabolism which accompanies differentiation of peripheral blood monocytes into alveolar macrophages. Am. J. Respir. Cell Mol. Biol. 11:153.[Abstract]
  31. Steinhilber, D., S. Hoshiko, J. Gunewald, O. Radmark, B. Samuelsson. 1993. Serum factors regulate 5-lipoxygenase activity in maturing HL-60 cells. Biochim. Biophys. Acta 1178:1.[Medline]
  32. Mackenzie, R., G. A. Coles, N. Topley, W. S. Powell, J. D. Williams. 1992. Down-regulation of cyclooxygenase product generation by human peritoneal macrophages. Immunology 76:648.[Medline]
  33. Sestini, P., L. Armetti, G. Gambora. 1996. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 53:572.
  34. Harizi, H., M. Juzan, C. Grosset, M. Rashedi, N. Gualde. 2001. Dendritic cells issued in vitro from bone marrow produce PGE2 that contributes to the immunomodulation induced by antigen-presenting cells. Cell. Immunol. 209:19.[Medline]
  35. You, Y., C. Y. A. Cheng, A. B. Shyu. 1992. U-rich sequence-binding proteins (URBPs) interacting with a 20-nucleotide U-rich sequence in the 3' untranslated region of c-fos mRNA may be involved in the first step of c-fos mRNA degradation. Mol. Cell. Biol. 12:2931.[Abstract/Free Full Text]
  36. Tilg, H., C. A. Dinarello, J. W. Mier. 1997. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol. Today 18:428.[Medline]
  37. Peters-Golden, M., R. W. McNish. 1993. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem. Biophys. Res. Commun. 196:147.[Medline]
  38. Dixon, R. A. F., R. E. Diehl, E. E. Opas, E. Rands, P. J. Vickers, J. F. Evans, J. W. Gillard, D. K. Miller. 1990. Requirement of 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343:282.[Medline]
  39. Rouzer, C. A., A. W. Ford-Hutchinson, H. E. Morton, J. W. Gillard. 1990. MK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-LO in ionophore challenged leukocytes. J. Biol. Chem. 265:1436.[Abstract/Free Full Text]
  40. Brock, T., R. W. McNish, M. Peters-Golgen. 1998. Capacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophages. Biochem. J. 319:519.
  41. Rola-Pleszczynski, M., J. Stankova. 1992. Leukotriene B4 enhances interleukin-6 production and IL-6 messenger accumulation in human monocytes in vitro: transcriptional and post-transcriptional mechanisms. Blood 80:1004.[Abstract/Free Full Text]
  42. Goulet, J. L., J. N. Snouwaer, A. M. Latour, T. M. Coffman, B. H. Koller. 1994. Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci. USA 91:12852.[Abstract/Free Full Text]
  43. Burka, J. F., N. A. M. Peterson. 1980. Evidence for lipoxygenase pathway involvement in allergic tracheal contraction. Prostaglandin 19:499.[Medline]
  44. Higgs, G. A., C. M. R. Bax, and S. Moncada. 1982. Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 9. B. Samuelsson, and R. Paoletti, eds. Raven, New York, p. 331.
  45. Walker, J. L. 1973. Advances in the Biosciences, Vol. 9. S. Bergstrom, and S. Bernhard, eds. Pergamon, Elmsford, p. 235.
  46. Bigby, T. D.. 2002. The yin and the yang of 5-lipoxygenase pathway activation. Mol. Pharmacol. 62:200.[Free Full Text]
  47. Peters-Golden, M., T. G. Brock. 2000. Intracellular compartmentalization of leukotriene synthesis. Am. J. Respir. Crit. Care Med. 161:36.[Abstract/Free Full Text]
  48. Hsieh, F. H., B. K. Lam, J. F. Penrose, K. F. Austen, J. A. Boyce. 2001. T helper cell type-2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: profound induction of leukotriene C4 synthase expression by interleukin 4. J. Exp. Med. 193:123.[Abstract/Free Full Text]
  49. Brock, T. G., J. A. Anderson, F. P. Fries, M. Peters-Golden, P. H. S. Sporn. 1999. Decreased leukotriene C4 synthesis accompanies adherence-dependent nuclear import of 5-lipoxygenase in human blood esinophils. J. Immunol. 162:1669.[Abstract/Free Full Text]
  50. Flammand, N., M. E. Surette, S. Picard, S. Bourgoin, P. Bourgeat. 2002. cAMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharmacol. 62:250.[Abstract/Free Full Text]
  51. Kambayashi, T., P. A. R. Wallin, H. G. Ljunggren. 2001. cAMP-elevating agents suppress dendritic cell function. J. Leukocyte Biol. 70:90.
  52. Zaitsu, M., Y. Hamasaki, M. Matsuo, A. Kukita, K. Tsuji, M. Miyazaki, R. Hayasaki, E. Muro, S. Yamamoto, I. Kobayashi, et al 2000. New induction of leukotriene A4 hydrolase by interleukin-4 and interleukin-13 in human polymorphonuclear leukocytes. Blood 96:601.[Abstract/Free Full Text]
  53. Fedyk, E. R., A. Adawi, R. J. Looney, R. P. Phipps. 1996. Regulation of IgE and cytokine production by cAMP implications for extrinsic asthma. Clin. Immunol. Immunopathol. 81:101.[Medline]
  54. Mellilo, E., K. L. Woolley, P. J. Mannig, R. M. Watson, P. O’Byrne. 1994. Effect of inhaled PGE2 on exercise induced bronchoconstriction in asthmatic subjects. Am. J. Respir. Crit. Care Med. 149:1138.[Abstract]
  55. Szczeklik, A., L. Mastalerz, E. Nizankowska, A. Cmiel. 1996. Protective and bronchodilatator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am. J. Respir. Crit. Care Med. 153:567.[Abstract]
  56. Peebles, R. S., Jr, K. Hashimoto, J. D. Morrow, R. Drowski, R. D. Collins, Y. Hashimoto, J. W. Christman, K. H. Kang, K. Jarzeka, J. Furlong, et al 2002. Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am. J. Respir. Crit. Care Med. 165:1154.[Abstract/Free Full Text]
  57. Humes, J. L., S. Sadowski, M. Galavage, M. Goldenberg, E. Subers, R. J. Bonney, F. A. Kuehl, Jr. 1982. Evidence for two sources of arachidonic acid for oxidative metabolism by mouse peritoneal macrophages. J. Biol. Chem. 257:1591.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Narushima, D. DiMeo, J. Tian, J. Zhang, D. Liu, and D. J. Berg
5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice
Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G477 - G488.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
S. W. Chung, A. Toriba, H. Y. Chung, B. P. Yu, T. Kameda, N. Tang, R. Kizu, and K. Hayakawa
Activation of 5-Lipoxygenase and NF-{kappa}B in the Action of Acenaphthenequinone by Modulation of Oxidative Stress
Toxicol. Sci., January 1, 2008; 101(1): 152 - 158.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Aritake, Y. Kado, T. Inoue, M. Miyano, and Y. Urade
Structural and Functional Characterization of HQL-79, an Orally Selective Inhibitor of Human Hematopoietic Prostaglandin D Synthase
J. Biol. Chem., June 2, 2006; 281(22): 15277 - 15286.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Christmas, K. Tolentino, V. Primo, K. Z. Berry, R. C. Murphy, M. Chen, D. M. Lee, and R. J. Soberman
Cytochrome P-450 4F18 Is the Leukotriene B4 {omega}-1/{omega}-2 Hydroxylase in Mouse Polymorphonuclear Leukocytes: IDENTIFICATION AS THE FUNCTIONAL ORTHOLOGUE OF HUMAN POLYMORPHONUCLEAR LEUKOCYTE CYP4F3A IN THE DOWN-REGULATION OF RESPONSES TO LTB4
J. Biol. Chem., March 17, 2006; 281(11): 7189 - 7196.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Zeyda, M. D. Saemann, K. M. Stuhlmeier, D. G. Mascher, P. N. Nowotny, G. J. Zlabinger, W. Waldhausl, and T. M. Stulnig
Polyunsaturated Fatty Acids Block Dendritic Cell Activation and Function Independently of NF-{kappa}B Activation
J. Biol. Chem., April 8, 2005; 280(14): 14293 - 14301.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
J. A. Green, R. A. Stockton, C. Johnson, and B. S. Jacobson
5-Lipoxygenase and cyclooxygenase regulate wound closure in NIH/3T3 fibroblast monolayers
Am J Physiol Cell Physiol, August 1, 2004; 287(2): C373 - C383.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
H. Harizi, C. Grosset, and N. Gualde
Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes
J. Leukoc. Biol., June 1, 2003; 73(6): 756 - 763.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles